Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
Department of Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200125, China
Organ Regeneration X Lab, LiSheng East China Institute of Biotechnology, Peking University, Nantong 226299, China
§ Lanyang Li, Jiping Liu, and Qi Cao contributed equally to this work.
Show Author Information
Hide Author Information
Highlights
• Rapid and efficient generation of uniformly-sized organoids from single cell suspensions
• Consistent gene expression in two high-fidelity ovarian cancer organoid models
• Uniformly-sized ovarian cancer organoids show consistent, reliable drug responses for personalized chemotherapy resistance tests
Graphical Abstract
View original imageDownload original image
This study explores the cultivation of uniformly-sized ovarian cancer organoids from single-cell suspensions, addressing challenges in high-throughput drug screening and providing insights into personalized treatment strategies against chemotherapy resistance.
Abstract
Ovarian cancer, a common gynecologic tumor, is associated with a high mortality, due to challenges in early detection within the reproductive system. According to our previous research, cultivating patient-specific organoids from mechanically sheared tissues can be utilized for drug response evaluation but has limitations for high-throughput screening efficiency due to their inconsistent size. In this research, we focused on organoids developed from single-cell suspensions to address the critical requirement for uniformity in organoid size. By the day 3 of culture, single-cell suspensions rapidly and spontaneously aggregated into spherical structures with a more consistent size. Notably, the organoids of sample OVA-37 were ten times larger after 8 days of culture. Transcriptomic analysis was used to compare the two organoid culture techniques, demonstrating that the variations between different organoid culture methods were minimal, with higher variability observed among patients. Gene set enrichment analysis (GSEA) revealed only minor discrepancies in specific pathways, such as TGF-β and tight junctions. Furthermore, treatment with carboplatin in a 96-well plate setup resulted in reproducible drug responses, as evidenced by coefficients of variation lower than 40%. This finding suggests that single-cell suspension-cultured organoids can be employed for reproducible high-throughput drug screening. This approach holds potential for personalized drug screening in ovarian cancer and may contribute to the development of novel therapeutic strategies.
Xie, W. W., Sun, H. Z., Li, X. D., Lin, F. K., Wang, Z. L., Wang, X. P. Ovarian cancer: Epigenetics, drug resistance, and progression. Cancer Cell International, 2021, 21(1): 434. https://doi.org/10.1186/s12935-021-02136-y
Konstantinopoulos, P. A., Matulonis, U. A. Clinical and translational advances in ovarian cancer therapy. Nature Cancer, 2023, 4(9): 1239–1257. https://doi.org/10.1038/s43018-023-00617-9
Matsui, T., Shinozawa, T. Human organoids for predictive toxicology research and drug development. Frontiers in Genetics, 2021, 12: 767621. https://doi.org/10.3389/fgene.2021.767621
Granat, L. M., Kambhampati, O., Klosek, S., Niedzwecki, B., Parsa, K., Zhang, D. The promises and challenges of patient-derived tumor organoids in drug development and precision oncology. Animal Models and Experimental Medicine, 2019, 2(3): 150–161. https://doi.org/10.1002/ame2.12077
Cao, Q., Li, L. Y., Zhao, Y. Q., Wang, C., Shi, Y. H., Tao, X., Cai, C. H., Han, X. X. PARPi decreased primary ovarian cancer organoid growth through early apoptosis and base excision repair pathway. Cell Transplantation, 2023 , 32. https://doi.org/10.1177/09636897231187996
Kondo, J., Inoue, M. Application of cancer organoid model for drug screening and personalized therapy. Cells, 2019, 8(5): 470. https://doi.org/10.3390/cells8050470
Jung, Y. H., Park, K., Kim, M., Oh, H., Choi, D. H., Ahn, J., Lee, S. B., Na, K., Min, B. S., Kim, J. A. et al. Development of an extracellular matrix plate for drug screening using patient-derived tumor organoids. BioChip Journal, 2023, 17(2): 284–292. https://doi.org/10.1007/s13206-023-00099-y
Mahbubi, R., Yousefi, N., Hamidieh, A., Gholizadeh, F., Sisakht, M. M. Tumor organoid as a drug screening platform for cancer research. Current Stem Cell Research & Therapy, 2023, 19(9): 1210–1250. https://doi.org/10.2174/011574888X268366230922080423
Spiller, E. R., Ung, N., Kim, S., Patsch, K., Lau, R., Strelez, C., Doshi, C., Choung, S., Choi, B., Juarez Rosales, E. F. et al. Imaging-based machine learning analysis of patient-derived tumor organoid drug response. Frontiers in Oncology, 2021, 11: 771173. https://doi.org/10.3389/fonc.2021.771173
Zhou, Z. L., Cong, L. L., Cong, X. L. Patient-derived organoids in precision medicine: Drug screening, organoid-on-a-chip and living organoid biobank. Frontiers in Oncology, 2021, 11: 762184. https://doi.org/10.3389/fonc.2021.762184
Wijler, L., Mateos, J. G., Nguyen, M., Staes, A. A. L., van Seters, L., Hasan, L. A., Tiroille, V., Herpers, B., Price, L., Madej, M. et al. Abstract 198: Pan-cancer assay-ready organoid drug screening with robust, reproducible and clinically-relevant output. Cancer Research, 2023, 83(7_Supplement): 198. https://doi.org/10.1158/1538-7445.AM2023-198
Yan, Y. T., Liu, J. L., Lawrence, A., Dykstra, M. J., Fannin, R., Gerrish, K., Tucker, C. J., Scappini, E., Dixon, D. Prolonged cadmium exposure alters benign uterine fibroid cell behavior, extracellular matrix components, and TGFB signaling. The FASEB Journal, 2021, 35(8): e21738. https://doi.org/10.1096/fj.202100354r
Pickup, M. W., Owens, P., Moses, H. L. TGF-β, bone morphogenetic protein, and activin signaling and the tumor microenvironment. Cold Spring Harbor Perspectives in Biology, 2017, 9(5): a022285. https://doi.org/10.1101/cshperspect.a022285
Nehme, Z., Roehlen, N., Dhawan, P., Baumert, T. F. Tight junction protein signaling and cancer biology. Cells, 2023, 12(2): 243. https://doi.org/10.3390/cells12020243
Li L, Liu J, Cao Q, et al. Crossroad of ovarian cancer organoid culture: Single cell suspension and mechanically sheared fragment. Cell Organoid, 2024,https://doi.org/10.26599/CO.2024.9410005
The articles published in this open access journal are distributed under the termsof the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution andreproduction in any medium, provided the original work is properly cited.
Comparative analysis of ovarian cancer organoid cultivation methods.
(a) Diagram illustrating the methodology for generating organoids from single-cell suspensions versus mechanically sheared fragments, highlighting procedural differences. (b) Brightfield microscopy visualization of ovarian cancer organoids 8 days post-culture, with scale bars for size reference. (c) Quantitative results of organoid size evolution over time, utilizing brightfield imaging to document growth dynamics across culture methods. The
y-axis represents the pixel area size calculated from ImageJ, while the
x-axis indicates the number of days in culture. The F denotes the fragment culture method, while S represents the single cell suspension culture method. (d) Quantitative comparison of organoid size evolution over time, utilizing brightfield imaging to document growth dynamics across culture methods. (e) Histological comparison via H&E staining of organoids derived from each method, demonstrating morphological consistency with scale bars provided.
Transcriptomic profiling of ovarian cancer organoids cultured by different methods.
(a) PCA showcasing the distinct genomic landscapes of organoids derived from single-cell suspensions and mechanically sheared fragments, with clustering by patient sample origin. (b) Sample correlation matrix highlighting the relationship between organoid culture methods, where intensity of color correlates with the degree of transcriptomic similarity. (c) Heatmap displaying differential gene expression patterns across samples, with normalization of raw counts to TPM and subsequent Z-score transformation for direct comparison. (d) Expression analysis of pivotal genes within cell cycle pathways, comparing their relative expression levels across the two organoid culture techniques. (e) GSEA revealing pathway variances between organoids derived via single-cell suspension and mechanical shearing, underscoring methodological impact on cellular function.
Establishment and growth dynamics of ovarian cancer organoids in 96-well plates.
(a) Detailed schematic showcasing the formation process of organoids from single-cell suspensions within the microenvironments of 96-well plates, emphasizing the self-aggregation mechanism. (b) High-resolution brightfield microscopy images displaying the comparative growth patterns of ovarian cancer organoids, cultured from single-cell suspensions and tissue fragmentation methods, at day 6, with the OG-OVA-41 sample serving as a case study. (c) Quantitative image analysis to evaluate the size uniformity of organoids developed from single-cell suspensions, underscoring the methodological advantages in promoting consistent organoid formation.
Organoid responses to chemotherapeutic treatment.
(a) Detailed schematic outlining the protocol for administering drug treatment to organoids, highlighting key observation intervals for assessing cellular health and viability. (b) Comparative brightfield microscopy visuals of ovarian cancer organoids post-chemotherapy, emphasizing the differential impact of treatment on organoids cultured via single-cell suspensions and those from tissue fragments. (c) A heatmap illustrating the quantitative cell viability, as indicated by log-transformed luminescence intensities, across varying concentrations of carboplatin, with data from quadruplicate samples underlining the consistency of response. (d) Analysis of variability in carboplatin response, presented as CV, across organoids derived from different patient samples, demonstrating the assay\'s reliability for drug sensitivity testing.
Cultivation dynamics of single-cell suspension-derived organoids in varied environments.
(a) Detailed schematic showcasing the methodology for continued cultivation of single-cell derived organoids, comparing suspension cultures against matrix gel environments. (b) Brightfield microscopy provides a visual comparison of organoid growth and morphology in suspension versus matrix gel conditions, with precise scale measurement for accurate size assessment. (c) Comparative histological analysis using H&E staining highlights the structural integrity and cellular detail of organoids cultivated under both conditions, with scale bars ensuring consistent magnification across samples.